Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health (Q38094297)

28 August 2017

title

Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health (English)

1 reference

28 August 2017

0 references

Peter J Mogayzel

1 reference

28 August 2017

Edward T Naureckas

1 reference

28 August 2017

Karen A Robinson

1 reference

28 August 2017

Gary Mueller

1 reference

28 August 2017

Denis Hadjiliadis

1 reference

28 August 2017

Jeffrey B Hoag

1 reference

28 August 2017

Lisa Lubsch

1 reference

28 August 2017

Leslie Hazle

1 reference

28 August 2017

Kathy Sabadosa

1 reference

28 August 2017

Bruce Marshall

1 reference

28 August 2017

Pulmonary Clinical Practice Guidelines Committee

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 April 2013

1 reference

American Journal of Respiratory and Critical Care Medicine

28 August 2017

published in

1 reference

28 August 2017

volume

187

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

680-689

1 reference

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Update on the methods of the U.S. Preventive Services Task Force: estimating certainty and magnitude of net benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Variability of airways hyper-reactivity and allergy in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Effect of high-dose ibuprofen in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Ivacaftor potentiation of multiple CFTR channels with gating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Molecular basis of defective anion transport in L cells expressing recombinant forms of CFTR

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Longitudinal association between medication adherence and lung health in people with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Sinonasal inhalation of dornase alfa in CF: A double-blind placebo-controlled cross-over pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

DNase in stable cystic fibrosis infants: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

A pilot study of zafirlukast as an anti-inflammatory agent in the treatment of adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Controlled Trial of Inhaled Budesonide in Patients with Cystic Fibrosis and Chronic BronchopulmonaryPseudomonas aeruginosaInfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Multicenter Randomized Controlled Trial of Withdrawal of Inhaled Corticosteroids in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1160OE

Inhaled bronchodilators for cystic fibrosis

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD003428.PUB2

Identifiers

DOI

10.1164/RCCM.201207-1160OE

1 reference

28 August 2017

1 reference